About Hansa Biopharma
Hansa Biopharma is a publicly listed company based in Lund (Sweden) founded in 2007. Therapeutics for rare immunological diseases are developed and commercialized. The company has 135 employees. Hansa Biopharma has completed 2 acquisitions, including Cartela AB and Immago Biosystems. Its chief executive, as recorded, is Soren Tulstrup. Its website hansabiopharma.com draws about 24 thousand monthly visits. Hansa Biopharma offers products and services including Imlifidase, HNSA-5487, and IDEFIRIX®. Its focus areas include Life Sciences, Immunology, Drugs and Autoimmune Diseases. Its legal entity is Hansa Biopharma AB.
Company details
Hansa Biopharma was founded in 2007 and is based in Lund, Sweden. Immunomodulating therapies are developed and commercialized within the biopharmaceutical sector, targeting rare immunological conditions. Focus areas include transplantation, autoimmune diseases, gene therapy, and oncology indications. Operations emphasize therapeutic advancement for unmet medical needs in these fields, with activities spanning research, development, and market introduction.
- Headquarters Lund, Sweden
- Employees 135
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website hansabiopharma.com
- Social LinkedIn X Facebook
- Legal Name Hansa Biopharma Ab
- Annual Revenue$24.13 M (USD)29.74as on Dec 31, 2025
- Net Profit-$57.99 M (USD)33.84as on Dec 31, 2025
- EBITDA-$52.53 M (USD)18.19as on Dec 31, 2025
- Latest Funding Round$30M (USD), Post-IPO
Mar 2026
- InvestorsNovaQuest Capital Management
& 1 more
- Employee Count135
- Investments & AcquisitionsCartela AB
& 1 more
Products & Services of Hansa Biopharma
Hansa Biopharma offers a comprehensive portfolio of products and services, including Imlifidase, HNSA-5487, and IDEFIRIX®.
Enzyme that inactivates IgG antibodies for autoimmune diseases treatment.
Targets IgG antibodies to halt immune responses in rare conditions.
Product for enabling transplantation procedures in patients.
Funding Insights of Hansa Biopharma
- Total Rounds 4
- Last Round Post-IPO — $30M
- First Round $65.46M
(Nov 2017)
- Investors Count 2
All 4 funding rounds of Hansa Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $30M | Post-IPO | – | – | |
| Jul 2022 | $70M | Post-IPO | – | – | |
| Jul 2020 | $121M | Post-IPO | – | – | – |
| Nov 2017 | $65.46M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Hansa Biopharma
Hansa Biopharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include NovaQuest Capital Management and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
| athyrium.com |
Investor details for Hansa Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hansa Biopharma
65 people are tracked at Hansa Biopharma (21 in leadership, 6 in board & advisors, 38 in team); the tracked headcount is 135.
| Name | Role | Group |
|---|---|---|
Soren Tulstrup | CEO & President | Leadership |
Helene Rahdevi | Head Of Clinical Operations | Leadership |
Mats Valfridsson | Senior Director CMC Operations | Leadership |
Emanuel Björne | Vice President Business Development & Alliance Management | Leadership |
Gina Ewy | Vice President Global Market Access | Leadership |
Angela Maldonado | Senior Medical Science Director - R&d | Leadership |
Henk Doude van Troostwijk | VP Commercial Excellence Global New Products | Leadership |
Marcus Dahlman | Head of Market Access Europe | Leadership |
Mark Wallace | VP Supply Chain | Leadership |
Max Sakajja | Vice President International Markets | Leadership |
Hitto Kaufmann | Chief R&D Officer | Leadership |
Evan Ballantyne | CFO | Leadership |
Benjamin Oskar | Global Market Access Director | Leadership |
Johan Oskarsson | Head of Information Technology | Leadership |
Katja Gustafsson | Vice President Regulatory Affairs | Leadership |
Magnus Korsgren | VP Product Development | Leadership |
Markus Roupé | Director of Biology | Leadership |
Isabelle Delabaye | EU Medical Affairs Director HansaBiopharma | Leadership |
Dr. Oliver Straub | Director (head) Medical Affairs Europe And International Markets | Leadership |
Yvonne Stenberg | Senior Director Translational Science | Leadership |
45 more people are available in the full profile.
Complete people profiles for Hansa Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Hansa Biopharma
Hansa Biopharma is a publicly listed company on the OMXSTO with ticker symbol HNSA in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Dec 2019
- Listed onBMV: HNSAN
- Listed entityHansa Biopharma AB
- Exchange sectorHealth technology
- ISINSE0002148817
- Share price34.72 SEK (+0.29% on the day) · 2026-10-14
- Market capitalisation3,523,042,628.00 SEK
- EPS (diluted, trailing year)-7.91 SEK
- Volume (last session)65,763
Financials of Hansa Biopharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 222.3M SEK | -534.1M SEK | -483.8M SEK |
| 2024 | 171.3M SEK | -807.2M SEK | -591.4M SEK |
| 2023 | 134.1M SEK | -831.7M SEK | -780.1M SEK |
| 2022 | 154.5M SEK | -611.1M SEK | -556.0M SEK |
| 2021 | 33.9M SEK | -548.3M SEK | -531.0M SEK |
Detailed financial statements for Hansa Biopharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hansa Biopharma
Hansa Biopharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cartela AB and Immago Biosystems.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of immunotherapeutics for cancer treatment | immago.co.uk | Cheltenham, United Kingdom | 2013 | Jul 2016 | •••• | |
Integrin-based therapies for osteoarthritis and rheumatoid arthritis are developed. | cartela.se | Lund, Sweden | 2000 | Jan 2008 | $617,783 |
Complete acquisition details for Hansa Biopharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Hansa Biopharma
6 dated milestones of Hansa Biopharma across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Hansa Biopharma is founded.
- Acquisition Acquires Cartela AB.
- Acquisition Acquires Immago Biosystems.
- Funding First funding round of $65.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.0M.
Web traffic of Hansa Biopharma
The website of Hansa Biopharma (hansabiopharma.com) receives about 23.6K visits a month and ranks #1,309,249 among all websites worldwide, #1,683 in Biotechnology and Pharmaceuticals.
- Monthly visits23.6K
▲ 29.1% vs previous month
- Unique visitors6.5K
per month
- Global rank#1,309,249
among all websites
- Category rank#1,683
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.7
- Average visit17 sec
- DevicesDesktop 19% · Mobile 81%
Websites whose visitors overlap most with Hansa Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| neurologylive.com | 100% | 170.9K | #299,267 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hansa Biopharma
Complete news archive for Hansa Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hansa Biopharma
Hansa Biopharma was founded in 2007 and raised its 1st funding round 10 years after it was founded.
Hansa Biopharma is headquartered in Lund, Sweden.
Soren Tulstrup is the CEO of Hansa Biopharma, as recorded in our data.
Hansa Biopharma has 135 employees.
Annual revenue of Hansa Biopharma is $24.13M as on Dec 31, 2025.
Hansa Biopharma was founded in 2007 and is based in Lund, Sweden. Immunomodulating therapies are developed and commercialized within the biopharmaceutical sector, targeting rare immunological conditions. Focus areas include transplantation, autoimmune diseases, gene therapy, and oncology indications. Operations emphasize therapeutic advancement for unmet medical needs in these fields, with activities spanning research, development, and market introduction.
Hansa Biopharma offers Imlifidase, HNSA-5487, and IDEFIRIX®.
Yes, Hansa Biopharma is publicly traded on OMXSTO under the ticker symbol HNSA.
Hansa Biopharma has made 2 acquisitions, including Cartela AB, and Immago Biosystems.
Hansa Biopharma has 2 investors. Key investors include NovaQuest Capital Management, and Athyrium Capital Management.
Hansa Biopharma operates through Hansa Biopharma Ab.